デフォルト表紙
市場調査レポート
商品コード
1462301

ミルベツキシマブソラブタンシン市場:市場規模、予測、市場洞察-2032年

Mirvetuximab Soravtansine Market Size, Forecast, and Drug Insight - 2032

出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 30 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
ミルベツキシマブソラブタンシン市場:市場規模、予測、市場洞察-2032年
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ミルベツキシマブソラブタンシン(IMGN853)は、葉酸受容体α(FRa)結合抗体、開裂可能なリンカー、および標的がん細胞を死滅させる強力なチューブリン標的薬剤であるメイタンシノイドペイロードDM4からなるファースト・イン・クラスのADCです。ミルベツキシマブソラブタンシンの抗FOLR1モノクローナル抗体部分は、細胞表面抗原FOLR1を標的として結合します。抗体と抗原が相互作用して内在化した後、免疫複合体はDM4を放出し、DM4はチューブリンに結合して微小管の集合/分解ダイナミクスを阻害し、それによってFOLR1を発現する腫瘍細胞の細胞分裂と細胞増殖を阻害します。葉酸受容体ファミリーの一員であるFOLR1は、様々な上皮由来のがん細胞で過剰発現しています。スルホ-SPDBリンカーは血流中での切断を防ぎ、多剤耐性腫瘍細胞に対する本剤の有効性を向上させる可能性があります。プラチナ製剤感受性の卵巣がんの後期治療薬として、またプラチナ製剤耐性およびプラチナ製剤感受性の両疾患における併用療法として研究されています。

今後数年間で、卵巣がんの市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、ミルベツキシマブソラブタンシンの優位性に影響を与える可能性のある機会を模索しています。卵巣がんに対する他の新興製品がミルベツキシマブソラブタンシンと厳しい市場競争を繰り広げることが予想され、近い将来に後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国における卵巣がん治療薬のミルベツキシマブソラブタンシン市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 卵巣がんにおけるミルベツキシマブソラブタンシンの概要

  • 製品の詳細
  • 臨床開発
    • 臨床研究
    • 臨床試験情報
    • 安全性と有効性
  • 規制のマイルストーン
  • その他の開発活動
  • 製品プロファイル

第3章 競合情勢(上市済み治療法)

第4章 競合情勢(後期段階の新興治療法)

第5章 ミルベツキシマブソラブタンシン市場評価

  • 卵巣がんにおけるミルベツキシマブソラブタンシン市場の見通し
  • 主要7ヶ国分析
    • 主要7ヶ国における卵巣がん治療薬ミルベツキシマブソラブタンシンの市場規模
  • 国別市場分析
    • 米国
    • ドイツ
    • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

図表

List of Tables

  • Table 1: Mirvetuximab soravtansine, Clinical Trial Description, 2023
  • Table 2: Mirvetuximab soravtansine, General Description
  • Table 3: Competitive Landscape (Marketed Therapies)
  • Table 4: Competitive Landscape (Late-stage Emerging Therapies)
  • Table 5: Mirvetuximab soravtansine Market Size in the 7MM, in USD million (2019-2032)
  • Table 6: Mirvetuximab soravtansine Market Size in the US, in USD million (2019-2032)
  • Table 7: Mirvetuximab soravtansine Market Size in Germany, in USD million (2019-2032)
  • Table 8: Mirvetuximab soravtansine Market Size in France, in USD million (2019-2032)
  • Table 9: Mirvetuximab soravtansine Market Size in Italy, in USD million (2019-2032)
  • Table 10: Mirvetuximab soravtansine Market Size in Spain, in USD million (2019-2032)
  • Table 11: Mirvetuximab soravtansine Market Size in the UK, in USD million (2019-2032)
  • Table 12: Mirvetuximab soravtansine Market Size in Japan, in USD million (2019-2032)

List of Figures

  • Figure 1: Mirvetuximab soravtansine Market Size in the 7MM, USD million (2019-2032)
  • Figure 2: Mirvetuximab soravtansine Market Size in the United States, USD million (2019-2032)
  • Figure 3: Mirvetuximab soravtansine Market Size in Germany, USD million (2019-2032)
  • Figure 4: Mirvetuximab soravtansine Market Size in France, USD million (2019-2032)
  • Figure 5: Mirvetuximab soravtansine Market Size in Italy, USD million (2019-2032)
  • Figure 6: Mirvetuximab soravtansine Market Size in Spain, USD million (2019-2032)
  • Figure 7: Mirvetuximab soravtansine Market Size in the United Kingdom, USD million (2019-2032)
  • Figure 8: Mirvetuximab soravtansine Market Size in Japan, USD million (2019-2032)
目次
Product Code: DIDM1213

"Mirvetuximab Soravtansine Market Size, Forecast, and Drug Insight - 2032" report provides comprehensive insights about mirvetuximab soravtansine for ovarian cancer in the seven major markets. A detailed picture of the mirvetuximab soravtansine for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the mirvetuximab soravtansine for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the mirvetuximab soravtansine market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.

Drug Summary:

Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRa)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family, is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent's efficacy in multidrug-resistant tumor cells. It is being studied in later line platinum-sensitive ovarian cancer and in combination in both platinum-resistant and platinum-sensitive diseases.

Scope of the Report:

The report provides insights into:

  • A comprehensive product overview including the mirvetuximab soravtansine description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
  • Elaborated details on mirvetuximab soravtansine regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the mirvetuximab soravtansine research and development activities in ovarian cancer across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around mirvetuximab soravtansine.
  • The report contains forecasted sales of mirvetuximab soravtansine for ovarian cancer till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
  • The report also features the SWOT analysis with analyst views for mirvetuximab soravtansine in ovarian cancer.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Mirvetuximab Soravtansine Analytical Perspective by DelveInsight

  • In-depth Mirvetuximab Soravtansine Market Assessment

This report provides a detailed market assessment of mirvetuximab soravtansine for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

  • Mirvetuximab Soravtansine Clinical Assessment

The report provides the clinical trials information of mirvetuximab soravtansine for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

  • In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence mirvetuximab soravtansine dominance.
  • Other emerging products for ovarian cancer are expected to give tough market competition to mirvetuximab soravtansine and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of mirvetuximab soravtansine in ovarian cancer.
  • Our in-depth analysis of the forecasted sales data of mirvetuximab soravtansine from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the mirvetuximab soravtansine in ovarian cancer.

Key Questions:

  • What is the product type, route of administration and mechanism of action of mirvetuximab soravtansine?
  • What is the clinical trial status of the study related to mirvetuximab soravtansine in ovarian cancer and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the mirvetuximab soravtansine development?
  • What are the key designations that have been granted to mirvetuximab soravtansine for ovarian cancer?
  • What is the forecasted market scenario of mirvetuximab soravtansine for ovarian cancer?
  • What are the forecasted sales of mirvetuximab soravtansine in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how are these giving competition to mirvetuximab soravtansine for ovarian cancer?
  • Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?

Table of Contents

1. Report Introduction

2. Mirvetuximab soravtansine Overview in ovarian cancer

  • 2.1. Product Detail
  • 2.2. Clinical Development
    • 2.2.1. Clinical studies
    • 2.2.2. Clinical trials information
    • 2.2.3. Safety and efficacy
  • 2.3. Regulatory Milestones
  • 2.4. Other Developmental Activities
  • 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Mirvetuximab soravtansine Market Assessment

  • 5.1. Market Outlook of Mirvetuximab soravtansine in ovarian cancer
  • 5.2. 7MM Analysis
    • 5.2.1. Market Size of Mirvetuximab soravtansine in the 7MM for ovarian cancer
  • 5.3. Country-wise Market Analysis
    • 5.3.1. Market Size of Mirvetuximab soravtansine in the United States for ovarian cancer
    • 5.3.2. Market Size of Mirvetuximab soravtansine in Germany for ovarian cancer
    • 5.3.3. Market Size of Mirvetuximab soravtansine in France for ovarian cancer
    • 5.3.4. Market Size of Mirvetuximab soravtansine in Italy for ovarian cancer
    • 5.3.5. Market Size of Mirvetuximab soravtansine in Spain for ovarian cancer
    • 5.3.6. Market Size of Mirvetuximab soravtansine in the United Kingdom for ovarian cancer
    • 5.3.7. Market Size of Mirvetuximab soravtansine in Japan for ovarian cancer

6. SWOT Analysis

7. Analysts' Views

8. Appendix

  • 8.1. Bibliography
  • 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options